Nonlinear pharmacokinetics of propafenone in rats and humans: Application of a substrate depletion assay using hepatocytes for assessment of nonlinearity

Drug Metabolism and Disposition

Volumn 33, Issue 6, 2005, Pages 726-732

  Komura, Hiroshi ^a   Iwaki, Masahiro ^a  

^a KINKI UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

HUMAN SERUM ALBUMIN; OROSOMUCOID; PROPAFENONE;

ANIMAL CELL; AREA UNDER THE CURVE; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DISTRIBUTION VOLUME; DRUG CLEARANCE; DRUG HALF LIFE; FEMALE; HUMAN; HUMAN CELL; LIVER CELL; LIVER METABOLISM; NONHUMAN; PLASMA PROTEIN BINDING; PRIORITY JOURNAL; PROTEIN DEPLETION; RAT; SPECIES DIFFERENCE;

ANIMALS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HEPATOCYTES; HUMANS; NONLINEAR DYNAMICS; PROPAFENONE; RATS; RATS, WISTAR; SPECIES SPECIFICITY; SUBSTRATE SPECIFICITY;

RATTUS NORVEGICUS;

EID: 18844363220     PISSN: 00909556     EISSN: None     Source Type: Journal    
DOI: 10.1124/dmd.104.002550     Document Type: Article

References (34)

1. Ansede JH and Thakker DR (2004) High-throughput screening for stability and inhibitory activity of compounds toward cytochrome P450-mediated metabolism. J Pharm Sci 93:239-255.
2. Aoyama T, Kotaki H, and Iga T (1990) Dose-dependent kinetics of methylphenidate enantiomers after oral administration of racemic methylphenidate to rats. J Pharmacobio-Dyn 13:647-652.
3. Botsch S, Gautier J-C, Beaune P, Eichelbaum M, and Kroemer HK (1993) Identification and characterization of the cytochrome P450 enzymes involved in N-dealkylation of propafenone: molecular base for interaction potential and variable disposition of active metabolites. Mol Pharmacol 43:120-126.
4. Boxenbaum H (1980) Interspecies variation in liver weight, hepatic blood flow and antipyrine intrinsic clearance: extrapolation of data to benzodiazepines and phenytoin. J Pharmacokinet Biopharm 8:165-176.
5. Clarke SE and Jeffrey P (2001) Utility of metabolic stability screening: comparison of in vitro and in vivo clearance. Xenobiotica 31:591-598.
6. Evans AM, Nation RL, Sansom LN, Bochner F, and Somogyi AA (1990) The relationship between the pharmacokinetics of ibuprofen enantiomers and the dose of racemic ibuprofen in humans. Biopharm Drug Dispos 11:507-518.
7. Funck-Brentano C, Kroemer HK, Lee JT, and Roden DM (1990) Propafenone. N Engl J Med 322:518-525.
8. Griffin SJ and Houston JB (2004) Comparison of fresh and cryopreserved rat hepatocyte suspensions for the prediction of in vitro intrinsic clearance. Drug Metab Dispos 32:552-558.
9. Han YH, Kato Y, and Sugiyama Y (1999) Nonlinear disposition kinetics of a novel antifolate, MX-68, in rats. J Pharmacol Exp Ther 291:204-212.
10. Hodgson J (2001) ADMET - turning chemicals into drugs. Nat Biotechnol 19:722-726.
11. Hollmann M, Brode E, Hotz D, Kaumeier S, and Kehrhahn OH (1983) Investigations on the pharmacokinetics of propafenone in man. Arzneim-Forsch 33:763-770.
12. Houston JB and Kenworthy KE (2000) In vitro-in vivo scaling of CYP kinetic data not consistent with classical Michaelis-Menten model. Drug Metab Dispos 28:246-254.
13. Israili ZH and Dayton PG (2001) Human alpha-1-glycoprotein and its interactions with drugs. Drug Metab Rev 33:161-235.
14. Iwatsubo T, Hirota N, Ooie T, Suzuki H, and Sugiyama Y (1996) Prediction of in vivo drug disposition from in vitro data based on physiological pharmacokinetics. Biopharm Drug Dispos 17:273-310.
15. Iwatsubo T, Hisaka A, Suzuki H, and Sugiyama Y (1998) Prediction of in vivo nonlinear first-pass hepatic metabolism of YM796 from in vitro metabolic data. J Pharmacol Exp Ther 286:122-127.
16. Kariv I, Rourick RA, Kassel DB, and Chung TD (2002) Improvement of "hit-to-lead" optimization by integration of in vitro HTS experimental models for early determination of pharmacokinetic properties. Comb Chem High Throughput Screen 5:459-472.
17. Kern A, Bader A, Pichlmayr R, and Sewing KF (1997) Drug metabolism in hepatocyte sandwich cultures of rats and humans. Biochem Pharmacol 54:761-772.
18. Kiriyama A, Nishiura T, Yamaji H, and Takada K (1999) Physiological based pharmacokinetics of KNI-272, a tripeptide HIV-1 protease inhibitor. Biopharm Drug Dispos 20:199-205.
19. 1-acid glycoprotein expression in liver and primary cultured hepatocytes. Biochem Pharmacol 62:1391-1397.
20. Komura H and Iwaki M (2005) Pharmacokinetics and metabolism of metoprolol and propranolol in the female DA and female Wistar rat: the female DA rat is not always an animal model for poor metabolizers of CYP2D6. J Pharm Sci 94:397-408.
21. Kroemer HK, Fischer C, Meese CO, and Eichelbaum M (1991) Enantiomer/enantiomer interaction of (S)- and (R)-propafenone for cytochrome P450IID6-catalyzed 5-hydroxylation: in vitro evaluation of the mechanism. Mol Pharmacol 40:135-142.
22. Kroemer HK, Mikus G, Kronbach T, Myer UA, and Eicheilbaum M (1989) In vitro characterization of the human cytochrome P-450 involved in polymorphic oxidation of propafenone. Clin Pharmacol Ther 45:28-33.
23. Lau YY, Sapidou E, Cui X, White RE, and Cheng K-C (2002) Development of a novel in vitro model to predict hepatic clearance using fresh, cryopreserved and sandwich-cultured hepatocytes. Drug Metab Dispos 30:1446-1454.
24. Ludden TM (1991) Nonlinear pharamacokinetics: clinical implications. Clin Pharmacokinet 20:429-446.
25. Naritomi Y, Terashita S, Kagayama A, and Sugiyama Y (2003) Utility of hepatocytes in predicting drug metabolism: comparison of hepatic intrinsic clearance in rats and humans in vivo and in vitro. Drug Metab Dispos 31:580-588.
26. Niazi SK, Alam SM, and Ahmad SI (1996) Dose dependent pharmacokinetics of naproxen in man. Biopharm Drug Dispos 17:355-361.
27. Obach RS and Reed-Hagen AE (2002) Measurement of Michaelis constants for cytochrome P450-mediated biotransformation reactions using a substrate depletion approach. Drug Metab Dispos 30:831-837.
28. Pang KS and Rowland M (1977) Hepatic clearance of drugs. I. Theoretical considerations of a "well-stirred" model and a "parallel tube" model. Influence of hepatic blood flow, plasma and blood cell binding and the hepatocellular enzymatic activity on hepatic drug clearance. J Pharmacokinet Biopharm 5:625-653.
29. Roberts SA (2001) High-throughput screening approaches for investigating drug metabolism and pharmacokinetics. Xenobiotica 31:557-589.
30. Shibata Y, Takahashi H, Chiba M, and Ishii Y (2002) Prediction of hepatic clearance and availability by cryopreserved human hepatocytes: an application of serum incubation method. Drug Metab Dispos 30:892-896.
31. Shimizu M, Ohota T, Kishida M, and Ogata H (2002) Nonlinear pharmacokinetics of aprinidine in guinea pigs. Drug Metab Pharmacokinet 17:292-299.
32. Takeuchi T, Tagawa Y, Hagihara K, Maeshiba Y, Yamashita K, Tsukuda R, and Yoshimura Y (2001) Nonlinear pharmacokinetics of TAK-044, a new endothelin antagonist, in rats. Biopharm Drug Dispos 22:221-230.
33. Yamaoka K, Tanigawara Y, Nakagawa T, and Uno T (1981) A pharmacokinetic analysis program (MULTI) for microcomputer. J Pharmacobio-Dyn 4:879-885.
34. Wong BK, Bruhin PJ, and Lin JH (1999) Dose-dependent plasma clearance of MK-826, a carbapenem antibiotic, arising from concentration-dependent plasma binding in rats and monkeys. J Pharm Sci 88:277-280.